PHSR Consulting Services LTD was founded over 7 years ago by its Managing Director, Doreen A Kahangire.
PHSR Consulting specializes in undertaking systematic literature/targeted reviews, health technology assessment, data pooling/meta-analyses (NMA/MAIC/ITC) as well as Real World Evidence (RWE) studies to inform clinical and decision making across a range of therapeutic areas including, but not limited to, Bone, Cardiovascular, Inflammation, Neurology, Nephrology and Oncology. Furthermore, we support research related projects that fall under a regulatory remit/obligation.
Strive for excellence in scientific research through continued partnerships with Industry, Academia, Patients, Physicians and Policy Makers.
To influence science-based research and Innovation across therapeutic areas.
Ethical, Team work, Communication and Accountability.
PHSR Consulting supports the identification, selection, critical appraisal, quality assessment and analysis of the best available evidence on research questions in line with credible research guidelines on the conduct and reporting of literature and systematic reviews such as CRD, COCHRANE, PRISMA.
We support the conduct and execution of HTAs across geographies including both the clinical and cost effectiveness evidence to inform dossier development. The HTAs are developed in line with the country requirements of reimbursement bodies such as NICE, AIFA, ANSM, AMNOG, etc.
We plan, design and execute Real-World Evidence (RWE) studies through observational research relative to a range of study designs i.e. chart reviews, database analyses, PROs, etc. Real world evidence is generated from evidence sources beyond clinical trials and thus, is increasing being recognised as a major component to inform reimbursement decisions across therapeutic areas. At PHSR Consulting, we aim to ensure RWE is incorporated in the respective services we offer including HTAs, NMA, reviews, etc.
We use these techniques to compare multiple treatments simultaneously in a single analysis by combining direct and indirect evidence within a network of randomised controlled trials as well as real-world estimates, where applicable, based on common comparator(s). Information generated from pooled analyses can inform GEVD development, HTA submissions and facilitate decision making on product strategies.
In line with our client’s business needs, we provide our services on a consultancy basis and tailor level of interaction depending on the ask. Additionally, we support project management including cross-functional alignment with both internal and external stakeholders to support the execution of the project at hand. The level of support is dependent on the complexity and urgency of the request and we ensure to work with the client to support timely execution of the project.
Using both published and unpublished evidence, we support the conduct and delivery of local, national and international guidelines across therapeutic disease areas in line with our client’s business needs. We also support the publication of these guidelines to inform clinical and policy making decisions. Our publication section showcases the guidelines we have been involved in.
We offer and tailor training services to suit business needs such as short cases on literature searches, critical appraisal, methodological conduct of HTAs, design and set up of RWE studies and medical writing.
Any scientific report or document should be composed in a clear, concise, and compliant way conveying the scientific information without any ambiguity and misrepresentation. We ensure that the documents related to clinical, non-clinical and other medical affairs related activities are aligned with industry standards. We support the writing and submission of publications (abstract/posters/manuscripts/letters/notes) to meet journal/congress/conference guidelines. Additionally, we advise on target journals to meet the methodologies of the studies at hand.
We support regulatory activities such as drafting and coordinating Orphan drug application submission (ODD/ODAs) and Risk Management Plans (RMPs), both core and across targeted markets in line with advice from regulatory bodies such as FDA, MHRA and EMA. Furthermore, we support the design, set up and conduct PASS/PAES to inform regulatory discussions and commitments to meet business needs.
Recommended treatment for early-stage NSCLC is complete surgical resection, with adjuvant chemotherapy in stage II–IIIA and select stage IB; however, approximately 30–70% of patients will experience disease recurrence within 5 years post-surgery…
read moreEGFR mutations occur in 10–50% of NSCLC patients globally. EGFR testing is recommended for NSCLC, with EGFR-TKIs recommended as the optimal first-line (1L) treatment for patients with advanced EGFRm NSCLC. This study investigated EGFR testing…
read moreComplete resection ± adjuvant chemotherapy is recommended for most patients (pts) with early-stage (I–IIIA) NSCLC; however, 5-year overall survival (OS) rates for this regimen decrease with advancing disease stage. Osimertinib is a third-generation…
read moreApproximately 22% of patients with NSCLC in South America harbour EGFR mutations. Clinical guidelines recommend EGFR testing as standard-of-care in advanced NSCLC, with EGFR-TKIs recommended as the optimal first line (1L) treatment. This study…
read moreEpidermal growth factor receptor (EGFR) mutations (EGFRm) are common oncogene drivers in non-small cell lung cancer (NSCLC). This real-world study explored treatment patterns and time to receive EGFRm test results in patients with advanced EGFRm…
read moreComplete surgical resection is the recommended treatment for early-stage NSCLC, followed by adjuvant chemotherapy for patients (pts) with resectable stage II–IIIA and select stage IB disease; however, many pts will experience disease recurrence…
read moreThere is little evidence on the relationship between achieved low-density lipoprotein cholesterol (LDL-C) levels and costs in patients on lipid-lowering therapy (LLT). We described healthcare resource use and costs (direct and indirect) by achieved…
read moreComplete surgical resection is the preferred treatment for early stage NSCLC, with adjuvant chemotherapy as the standard of care in resected stage II/III and select stage IB NSCLC
read morePrevalence of EGFRm in NSCLC is estimated to be approximately 30%, although this varies by country and region. This global survey investigated physician behaviours related to genetic testing patterns in early (I/II/IIIa) and advanced (IIIb/IIIc/IV…
read morePrevalence of EGFRm in NSCLC is estimated to be approximately 30%, although this varies by country and region. This global survey investigated physician behaviours related to genetic testing patterns in early (I/II/IIIa) and advanced (IIIb/IIIc/IV…
read moreOsteoporosis is a skeletal disease that may result in low-trauma fracture if untreated. Among men and women ≥ 70 years untreated for osteoporosis, 30% (43,514) sustained at least one post-index fracture. Care for patients with osteoporosis diagnosis…
read moreHistorically, standard of care for early-stage NSCLC was complete surgical resection, with adjuvant chemotherapy in resected stage II/III and select stage IB NSCLC. However, recurrence rates remained high, increasing with disease stage.
read moreArchives of Osteoporosis is an international multidisciplinary journal which is a joint initiative of the International Osteoporosis Foundation and the National Osteoporosis Foundation of the USA. The journal will highlight the specificities of…
read moreAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in Italy, accounting for 22% of total deaths. Lowering low-density lipoprotein cholesterol (LDL-C) levels reduces the risk of cardiovascular (CV) events; thus, lipid…
read moreOsteoporosis is a skeletal disease that may result in low-trauma fracture if untreated. Among men and women ≥ 70 years untreated for osteoporosis, 30% (43,514) sustained at least one post-index fracture. Care for patients with osteoporosis diagnosis…
read moreOsteoporosis-related fragility fractures increase the risk of subsequent fractures and are associated with substantial morbidity and mortality. Emphasis should be placed on the prevention of recurrent fractures, which will decrease both the clinical…
read moreEGFR mutations are known oncogene drivers in NSCLC. Guidelines recommend EGFRm testing as standard of care in patients with advanced NSCLC. In EGFRm advanced NSCLC patients, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the preferred first-line…
read moreIn NSCLC, approximately 10–20% of Caucasian patients and up to 50% of Asian patients harbour EGFRm. Clinical guidelines recommend EGFRm testing as standard of care in advanced NSCLC, with EGFR-TKIs recommended as the optimal first-line (1L) treatment…
read moreEGFR mutations are known oncogene drivers in NSCLC. Guidelines recommend EGFRm testing as standard of care in patients with advanced NSCLC. In EGFRm advanced NSCLC patients, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the preferred first-line…
read moreGiven the role of EGFRm in the development of NSCLC, EGFR is an established target for treating the disease. While EGFR-TKIs are the recommended first-line (1L) treatment option for advanced EGFRm NSCLC, there is limited evidence describing the use…
read moreIn patients at risk of cardiovascular (CV) events, the effectiveness of lipid-lowering therapies (LLT) is affected by both intensity and adherence. Our study evaluated the association between LLT intensity (statin and/or ezetimibe) and adherence, and…
read moreVarious surveys and studies in recent years have shown that many patients with osteoporosis do not receive any specific treatment or follow-up care despite their diagnosis. This study examines the consequences of untreated osteoporosis. For this…
read moreThe clinical and cost burden following an initial ORF is high. Timely treatment may lower the incidence of recurrent fractures, and reduce the morbidity, mortality and resource use/costs among these patients.
read more#117. Outcomes of relapsed/refractory multiple myeloma patients receiving carfilzomib-based therapy in routine practice; results of a single-centre Austrian registry (2020)
read moreDetailed epidemiologic descriptions of large populations of advanced stage ovarian cancer patients have been lacking to date. This study aimed to describe the patient characteristics, treatment patterns, survival, and incidence rates of health…
read moreResource utilisation and costs associated with achieved LDL-C levels in patients following a myocardial infarction treated with lipid lowering therapies in Spain (28 August 2020) – European Society of Cardiology ESC
read moreResource utilisation and costs associated with achieved LDL-C levels in patients following a myocardial infarction treated with lipid lowering therapies in Spain (28 August 2020) – European Society of Cardiology ESC
read morePMS27 Clinical and Economic Burden Following Osteoporosis-Related Fracture(s) in France (2020) – Top 10% highest review score; Certificate of Recognition from ISPOR.
read moreRe-hospitalization due to subsequent Cardiovascular events in secondary prevention patients treated with Lipid Lowering therapies in Italy (2019)
read moreAdherence and Treatment Intensity of Lipid-Lowering therapy in patients with history of Myocardial Infarction in France using SNDS Database(2019)
read moreRate of fractures leading to hospitalisation and healthcare burden in untreated Osteoporosis elderly patients in Germany: An INGEF Healthcare insurance Database Analysis
read moreThe 1948, Universal Declaration of Human Rights states that "adequate housing" is a basic human right. A fact sheet from the Office of the United Nations High Commissioner for Human Rights and UN Habitat describes the right, and defines what is meant…
read moreThis report assesses the relationship of household crowding to various health effects. A systematic review of this topic was conducted to support the development of the World Health Organization’s (WHO) Housing and health guidelines. The aim of this…
read moreHigh-risk neuroblastoma is a rare malignant disease and mainly aDects infants and very young children. The tumors mainly develop in the core part (medulla) of the adrenal gland. The adrenal gland is located on top of the kidneys. A tumor increasing…
read moreNeuroblastoma is a rare malignant disease and mainly affects infants and very young children. The tumors mainly develop in the adrenal medullary tissue and an abdominal mass is the most common presentation. About 50% of patients have metastatic…
read more